NEW YORK (GenomeWeb) – The National Cancer Institute this month said that it has renewed a program under which it will fund the use of biosamples obtained through the Prostate, Lung, Colorectal, and Ovarian Cancer Screening (PLCO) trial in order to advance research into the etiology and early detection of cancer.

The NCI said it will support a wide range of cancer research including biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.